Friday, July 20, 2018
 
 
Company News: Page (1) of 1 - 07/09/18 Email this story to a friend. email article Print this page (Article printing at MyDmn.com).print page facebook
Neosanté Health Solutions, creators of Delictase®, on new Royal Children's Hospital infant colic study
 
(July 09, 2018)

BOCA RATON, Fla., July 9, 2018 /PRNewswire/ -- Neosanté Health Solutions, manufacturers of Delictase®, a lactase enzyme supplement, discuss a study about the possibility of long-term effects baby colic has into adulthood, and how its unique product can prevent the baby colic from happening in the first place.

According to the study conducted by Dr. Georgie Bell from the Royal Children's Hospital, one-in-five families have a child who has suffered from baby colic and despite the lack of any long-term effects into adulthood, the pain and suffering must still be dealt with during infancy.

"The etiology of colic is not fully determined; therefore, there is not one easy-to-use, single treatment for all cases," João Santos, CEO at Neosanté, said. "Infant colic can be present due to incorrect feeding techniques, mother's diet, home environment, lactase deficiency or health problems."



In comparison with probiotics such as Lactobacillus reuteri, which address baby colic symptoms but don't attack the cause of the problem, Delictase Oral Drops, a lactase enzyme, has been proven to be the only treatment that actually addresses the cause of infant colic.

"It is accepted by modern science that most of the baby's development is done after birth," Santos said. "A percentage of babies are born with a health condition called 'Transient Lactase Deficiency,' which means that babies can't produce enough lactase endogenously for the first four-to-five months of life. Therefore, babies can't digest lactose."

The Delictase® food supplement has just the right amount of lactase enzyme in the form of drops or powder encased within capsules, to help treat digestive disorders like colic caused by transient lactose intolerance in newborns and infants.

"Although not a disease, infant colic is a health condition that shouldn't be neglected," Santos said. "Having an impact on the baby and the family, this is a condition that can last for about three to four months, and it is not fair nor ethical to leave families suffering this long."

Some of the symptoms that may contribute to baby colic include lactose intolerance, food allergy, intestinal microflora disorders, incorrect feeding technique and psychological factors. Lactose is the main carbohydrate found in breast milk and infant formulas. For this reason, it is important to treat transient lactose intolerance to allow babies to receive the necessary glucose and galactose intake they need in order for their bodies to function and develop properly.

Delictase Oral Drops are safe for newborns, doesn't need incubation before use, and doesn't need refrigeration. It is manufactured in the European Union, certified with Good Manufacturing Practices (GMP), and it's currently sold in more than 20 countries located on four continents.

"This product enhances a proper digestion of lactose by naturally eliminating the cause of colic," Santos said. "It provides an external source of lactase, the enzyme necessary for the correct digestion of lactose."

For more information on Delictase® oral drops, visit www.delictase.com. For more information on Neosante Health Solutions, visit www.neosante-hs.com.

Please direct inquiries to:
Chloe Sommers, 561-544-0719
[email protected]

Cision View original content:http://www.prnewswire.com/news-releases/neosante-health-solutions-creators-of-delictase-on-new-royal-childrens-hospital-infant-colic-study-300676101.html

SOURCE Neosanté Health Solutions

Copyright 2014 PR Newswire. All Rights Reserved


Page: 1


Related Keywords:Diet,Disease,Pregnancy,Surgery,Pregnancy,Science,Family,
Related Sites: DMN Newswire ,   HTN - Health Technology Net
Related Newsletter: Tutorial Finder ,   Review Seeker ,   DMN Newswire Newsletter
 
 
 
 
 
 
 
Seniors

Drugs
  • Healthcare IT Market 2018 - 2023 with SWOT Analysis regarding upcoming Changes and Technology Adaptations in Global Healthcare Sector
  • Vision Care Product Market To Witness Enhanced Growth Owing To Rising Occurrence Of Eye Disorders Till 2021 | Million Insights
  • Global Prosthetic Heart Valve Market Reaching at a CAGR of +12.70% by Geography, Deployment Model, Component, and Key players are Boston Scientific Cardiology, CryoLife, Inc., Abbott
  • Trauma Fixation Global Market to Register Steady Expansion During 2018-2025
  • Global Surgical Apparel Market Will Reach USD 2,966.58 million by 2024: Zion Market Research

    Cancer
  • Mesothelioma is a Deadly Cancer and it’s Completely Preventable
  • HedgePath Pharmaceuticals Granted Exclusive Option to License UCONN's Patented Chemical Analogues of Itraconazole
  • Alligator Bioscience Submits Application to Start Clinical Phase I Study in Cancer Patients with ATOR-1015, a Unique CTLA-4 and OX40 Binding Antibody
  • Yisheng Biopharma Announces Opening of New Business Divisions in Cambodia, Expanding Presence within Southeast Asia
  • Omega-3 Market to Reach US$ 16.37 Bn by 2023, Globally - QYResearch.com
  •  
     
     
     
     
     





    Our Privacy Policy --- About The Health Technology - Contact Us - Advertise With Us - Privacy Guidelines